Diabetes
Areas of Partnership Interest
- Amelioration of insulin resistance
- Improvement in pancreatic beta cell function/survival
- Non-invasive approaches to measuring islet cell mass/survival
- Identification of patients with high cardiovascular risk (that improves on risk assessment by standard phenotype scores like Framingham and UKPDS scores)
- Reduction of cardiovascular risk factors
- Identification of subjects at higher risk of diabetes disease progression (e.g., accelerated loss of beta cell function)
- Surrogate measure of insulin sensitivity with high correlation to gold standard of euglycemic clamp
- Identification of patients at higher risk of developing diabetic complications
- Surrogate measure of early impact on diabetic complications
Areas of Less Interest
- Continuous monitoring technology (no interest in development)
"Pfizer is committed to flexible, transparent and mutually beneficial long-term relationships with its partners. By joining forces, we can bring quality therapies to patients worldwide. Let's work together for a healthier world."

